🧪
hypothesis

Gut-derived butyrate reprograms microglia for amyloid clearance via HDAC2 inhibition

Hypothesis

Gut-derived butyrate reprograms microglia for amyloid clearance via HDAC2 inhibition

Specific butyrate-producing gut bacteria (e.g., Faecalibacterium, Roseburia) generate systemic butyrate that crosses the blood-brain barrier and inhibits hippocampal microglial HDAC2, leading to hyperacetylation of transcription factors .
🧬 HDAC2🩺 alzheimers🎯 Composite 52%💱 $0.59▼4.9%proposed
neurodegeneration
EvidencePending (0%)📖 5 cit🗣 1 debates 5 support 1 oppose
✓ All Quality Gates Passed
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite52%

🧪 Overview

Specific butyrate-producing gut bacteria (e.g., Faecalibacterium, Roseburia) generate systemic butyrate that crosses the blood-brain barrier and inhibits hippocampal microglial HDAC2, leading to hyperacetylation of transcription factors that upregulate TREM2-independent phagocytic pathways. This enhances microglial amyloid-beta uptake and lysosomal degradation while suppressing NLRP3 inflammasome activation. Testable prediction: Germ-free AD mice colonized with butyrate-producing bacteria or treated with sodium butyrate will show reduced amyloid plaque burden, increased microglial amyloid phagocytosis rates ex vivo, and decreased IL-1β and caspase-1 levels, compared to controls.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Gut Butyrate Deficiency<br/>HDAC2 Dysregulation"]
    B["Microglial Amyloid<br/>Clearance Impairment"]
    C["HDAC2 Inhibition<br/>Microglial Reprogramming"]
    D["Butyrate Restoration<br/>Epigenetic Reset"]
    E["HDAC2-Butyrate Axis<br/>as AD Prevention Target"]
    F["Microglial<br/> epigenetic Therapy"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix5 supports1 contradicts
Supports
TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.
Cell2022PMID:36306735medium
Supports
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
Nat Med2020PMID:31932797medium
Supports
TREM2, microglia, and Alzheimer's disease.
Mech Ageing Dev2021PMID:33516818medium
Supports
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.
Cell2017PMID:28802038medium
Supports
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Immunity2017PMID:28930663medium
Contradicts
CNS effects of sodium butyrate require supraphysiological doses administered systemically (≥300 mg/kg in rodents) that gut-derived butyrate cannot achieve in CSF; colonocyte beta-oxidation and hepatic first-pass metabolism rapidly catabolize portal butyrate, leaving negligible concentrations to cross the BBB
PMID:33785315strong
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — HDAC2

No curated PDB or AlphaFold mapping for HDAC2 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for HDAC2 from GTEx v10.

Cerebellar Hemisphere19.9 Cerebellum14.5median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for HDAC2 →

No DepMap CRISPR Chronos data found for HDAC2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.4%
Volatility
Medium
0.0459
Events (7d)
2
Price History
▼4.9%

💾 Resource Usage

LLM Tokens
16,120
$0.0967
Total Cost
$0.0967

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF 5xFAD germ-free mice receive daily intraperitoneal sodium butyrate (300 mg/kg) for 8 weeks starting at 4 months of age, THEN hippocampal amyloid plaque burden will decrease by ≥30% compared to vehi≥30% reduction in hippocampal amyloid plaque burden after 8 weeks of sodium butyrate treatment, with increased co-localization of IBA1+ microglia with thioflavi— no observation —pending0.65
IF germ-free APP/PS1 mice are colonized with human-derived Faecalibacterium prausnitzii (butyrate-producer) vs. Escherichia coli (non-butyrate-producer) via oral gavage for 6 weeks, THEN microglial HD≥40% reduction in microglial HDAC2 activity (nuclear extraction + fluorometric assay) and ≥60% increase in Aβ42 uptake by cultured hippocampal microglia isolate— no observation —pending0.55
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF 5xFAD germ-free mice receive daily intraperitoneal sodium butyrate (300 mg/kg) for 8 weeks starting at 4 months of age, THEN hippocampal amyloid plaque burden will decrease by ≥30% compared to vehicle-treated 5xFAD germ-free controls, as measured by thioflavin-S stereology.
Predicted outcome: ≥30% reduction in hippocampal amyloid plaque burden after 8 weeks of sodium butyrate treatment, with increased co-localization of IBA1+ microglia with
Falsification: No significant difference (p>0.05) in hippocampal amyloid plaque burden between sodium butyrate-treated and vehicle-treated groups, or plaque burden increases in the treatment group.
pendingconf 55%
IF germ-free APP/PS1 mice are colonized with human-derived Faecalibacterium prausnitzii (butyrate-producer) vs. Escherichia coli (non-butyrate-producer) via oral gavage for 6 weeks, THEN microglial HDAC2 activity will decrease by ≥40% and ex vivo amyloid phagocytosis rate will increase by ≥60% in th
Predicted outcome: ≥40% reduction in microglial HDAC2 activity (nuclear extraction + fluorometric assay) and ≥60% increase in Aβ42 uptake by cultured hippocampal microgl
Falsification: No significant difference in microglial HDAC2 activity between colonized groups, or HDAC2 activity increases rather than decreases in the Faecalibacterium group; phagocytosis rates remain equivalent o
View on SciDEX ↗